In general, the histamine type-2 receptor antagonists (H2RA) enjoy an enviable record of safety. These agents, notably cimetidine, have been studied extensively in clinical trials, case reports, and worldwide drug use reporting systems. Of the available agents (cimetidine, famotidine, nizatidine, and ranitidine) several similarities exist from compound to compound and use data to support that each of the agents is equally safe and efficacious in equipotent dosing. A review of H2RA pharmacology, pharmacokinetics, adverse effects, and drug interactions is included to provide the clinician with a basis for rational selection and use of an H2RA.
Get full access to this article
View all access options for this article.
References
1.
Hurwitz A., Carter CA: The pharmacology of antiulcer drugs. Ann Pharmacother23:510-6, 1990
2.
Freston JW: Overview of medical therapy of peptic ulcer disease. GastroenterologyClin North Am19:121-40, 1990
3.
Souney PF, Stoukides CA: Pharmacoeconomic aspects and formulary considerations related to histamine2-receptor antagonists. Ann Pharmacother23:529-35, 1990
4.
Levine JB: Safety profile of H2-receptor antagonists: Current status of famotidine . J Intern Med Res17:48A-53A, 1989 (suppl 1)
5.
Richter JM, Colditz GA, Huse M., et al: Cimetidine and adverse reactions: A meta-analysis of randomized clinical trials of short-term therapy. Am J Med87:278-84, 1989
Package insert. Pepoid (famotidine). West Point, PA, MSD, 1991
9.
Package insert. Axid (nizatidine). Indianapolis, IN, Eli Lilly, 1991
10.
Package insert. Zantac (ranitidine). Research Triangle Park, NC, Glaxo, 1991
11.
Dent J (ed): Concepts and controversies in oesophageal reflux disease-an interactive evaluation of management trends. Presented at the 13th International Congress of Gastroenterology, Rome, Italy, September, 1988. Scand J Gastroenterol 24:168, 1989 (suppl)
Hogan WJ: Gastroesophageal reflux disease: An update on management. J Clin Gastroenterol12:S21-28, 1990 (suppl 2)
14.
Palmer RH, Frank WO, Rockhold FW, et al: Cimetidine 800 mg twice daily for healing erosions and ulcers in gastroesophageal reflux disease. J Clin Gastroenterol12:S29-34, 1990 (suppl 2)
15.
Tytgat Gnj: Drug therapy of reflux oesophagitis: An update. Scand J Gastroenterol24, 1989 (suppl 168)
16.
Sperenza V. : Cimetidine and antacid prophylaxis of acute upper gastrointestinal bleeding in high-risk patients. Controlled, randomized trial. Am J Surg141:339-341, 1981
17.
Bresalier RS : Prophylaxis of stress-related gastric mucosal hemorrhage: a critical appraisal. Intensive Care Med5:5-6,1990
18.
Bruegge Wfv , Peura DA: Stress-related mucosal damage: Review of drug therapy. J Clin Gastroenterol12:S35-40, 1990 (suppl 2)
19.
Friedman CJ , Oblinger MJ, Suratt PM, et al: Prophylaxis of upper gastrointestinal hemorrhage in patients requiring mechanical ventilation . Crit Care Med10:316-319, 1982
20.
Kaarlstadt RG, Iberti TJ, Silverstein J., et al: Comparison of cimetidine and placebo for the prophylaxis of upper gastrointestinal bleeding due to stress-related gastric mucosal damage in the intensive care unit. Intensive Care Med5:26-32,1990
21.
Kingsley AN : Prophylaxis for acute stress ulcers. Antacids or cimetidine. Am Surg51:545-547,1985
22.
Lucas CE: Stress ulceration: The clinical problem. World J Surg5:139-151,1981
23.
Peura DA, Johnson LF: Cimetidine for prevention and treatment of gastroduodenal mucosal lesions in patients in an intensive care unit. Ann Intern Med103:173-177,1985
24.
Poleski MH, Spainer AH: Cimetidine versus antacids in the prevention of stress erosions in critically ill patients. Am J Gastroenterol81:107-111, 1986
25.
Reid SR, Bayliff CD: The comparative efficacy of cimetidine and ranitidine in controlling gastric pH in critically ill patients. Can Anaesth Soc J33:287-293, 1986
26.
Schuster DP , Rowley H., Feinstein S., et al: Prospective evaluation of the risk of upper gastrointestinal bleeding after admission to medical intensive care unit. Am J Med76:623-630, 1984
27.
Shuman RB, Shuster DP, Zuckerman GR: Prophylactic therapy for stress ulcer bleeding: A reappraisal. Ann Intern Med106:562-567, 1987
28.
Silen W., Merhav A., Simpnson Jnl: The pathophysiology of stress ulcer disease. World J Surg5:165-72, 1981
29.
Weigelt JA, Aurbakken CM, Gewertz BL, et al: Cimetidine versus antacid in prophylaxis for stress ulceration . Arch Surg116:597-601, 1981
30.
Melnyk CS: Clinical spectrum and therapeutic strategies for managing gastroesophageal reflux disease. Evolving concepts in formulary drug management , Scottsdale, AZ, February, 1991
31.
Colin-Jones DG, Langman Mjs, Lawson DH, et al: Postmarketing of the safety of cimetidine: Twelve-month morbidity report. Q J Med54:253-268, 1985
32.
Davis TG, Pickett DL, Schlosser JH: Evaluation of a worldwide spontaneous reporting system with cimetidine . JAMA243:1912-1914, 1980
Humphries TJ , Myerson RM, Gifford LM, et al: A unique postmarket outpatient surveillance program of cimetidine. Report on phase II and final summary. Am J Gastroenterol79:593-596, 1984
35.
Sabesin S.: Safety issues with H2-receptor antagonists in the treatment of gastrointestinal disease in the elderly. PractGastroenterol17-21, 1988
36.
Inman Whw: Zantac. Pem News, August:9-13, 1983
37.
Cantu TG, Korek JS: Central nervous system reactions to histamine-2 receptor blockers . Ann Intern Med114:1027-1034,1991
38.
Spychal RT, Wickham Nwr: Thrombocytopenia associated with ranitidine. Br Med J291:1687, 1985 (abstr)
39.
Drsa EJ, Mutnick AH, Lam W., et al: Cimetidine-associated adverse reaction. Ann Pharmacother24:581-583, 1990
Jeffereys DB , Vale JA: Cimetidine and bradycardia. Lancet1:828,1978
42.
Totterman K. , Kupari M., Paakkari I., et al: Acute cardiovascular effects of intravenous cimetidine. Acta Med Scand217:277-80, 1985
43.
Lee PK, Cai CL, Lok Asf, et al: Hemodynamic responses to intravenous cimetidine in subjects with normal lung function and in subjects with chronic airway obstruction . Br J Clin Pharmacol11:339-43, 1981
44.
Selby D.: Cardiovascular effects of cimetidine. Med J Aust1:190, 1981 (letter)
45.
Coursin DB, Farin-Rusk C., Springman SR, et al: The hemodynamic effects of intravenous cimetidine versus ranitidine in intensive care unit patients: A double-blind, prospective, cross-over study . Anesthesiology69:975-8, 1988
46.
Freston JW: Safety perspectives on parenteral H2-receptor antagonists. Am J Med83:58-67, 1987 (suppl 6A)
47.
Freston JW: Cimetidine. II. Adverse reactions and patterns of use. Ann Intern Med97:728-734,1982
48.
Epstein CM, Kloppe J.: Ranitidine headache. Headache25:392-393, 1985
49.
Hermann R., Shaw RG, Fone DJ: Ranitidine-associated recurrent acute pancreatitis. Aust NZ J Med20:243-244, 1990
50.
Nazario M.: The hepatic and renal mechanisms of drug interactions with cimetidine . Drug Intell Clin Pharm20:342-348, 1986
51.
Black: Am J Med83:68,1987 (suppl 6A)
52.
Siepler J., Trudeau W., Musallam N., et al: An analysis of the impact of cimetidine and ranitidine on theophylline toxicity (abstract). Gastroenterology96:472, 1989 (abstr 472)
53.
Jarowenko MV , Van Buren CT, Kramer WG, et al: Ranitidine, cimetidine, and the cyclosporine-treated recipient. Transplantation42:311-312, 1986
54.
Greenblatt DJ, Shader RI, Abernathy DR: Current status of benzodiazepines (part 1 of 2). N Engl J Med309:354-358, 1983
55.
Greenblatt DJ, Shader RI, Abernathy DR: Current status of benzodiazepines (part 2 of 2). N Engl J Med309:410-415, 1983a
